TY - JOUR
T1 - Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial
AU - Meduri, Bruno
AU - Baldissera, Antonella
AU - Iotti, Cinzia
AU - Scheijmans, Luc J. E. E.
AU - Stam, Marcel R.
AU - Parisi, Salvatore
AU - Boersma, Liesbeth J.
AU - Ammendolia, Ilario
AU - Koiter, Eveline
AU - Valli, Mariacarla
AU - Scandolaro, Luciano
AU - Busz, Dianne
AU - Stenfert Kroese, Marika C.
AU - Ciabatti, Selena
AU - Giacobazzi, Patrizia
AU - Ruggieri, Maria P.
AU - Engelen, Antoine
AU - Munafo, Tindara
AU - Westenberg, A. Helen
AU - Verhoeven, Karolien
AU - Vicini, Roberto
AU - D'Amico, Roberto
AU - Lohr, Frank
AU - Bertoni, Filippo
AU - Poortmans, Philip
AU - Frezza, Giovanni P.
PY - 2023/4/20
Y1 - 2023/4/20
N2 - PURPOSEThe results in terms of side effects vary among the published accelerated partial-breast irradiation (APBI) studies. Here, we report the 5-year results for cosmetic outcomes and toxicity of the IRMA trial.METHODSWe ran this randomized phase III trial in 35 centers. Women with stage I-IIA breast cancer treated with breast-conserving surgery, age 49 years, were randomly assigned 1:1 to receive either whole-breast irradiation (WBI) or external beam radiation therapy APBI (38.5 Gy/10 fraction twice daily). Patients and investigators were not masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence. We hereby present the analysis of the secondary outcomes, cosmesis, and normal tissue toxicity. All side effects were graded with the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Radiation Morbidity Scoring Schema. Analysis was performed with both intention-to-treat and as-treated approaches.RESULTSBetween March 2007 and March 2019, 3,309 patients were randomly assigned to 1,657 WBI and 1,652 APBI; 3,225 patients comprised the intention-to-treat population (1,623 WBI and 1,602 APBI). At a median follow-up of 5.6 (interquartile range, 4.0-8.4) years, adverse cosmesis in the APBI patients was higher than that in the WBI patients at 3 years (12.7% v 9.2%; P =.009) and at 5 years (14% v 9.8%; P =.012). Late soft tissue toxicity (grade 3: 2.8% APBI v 1% WBI, P <.0001) and late bone toxicity (grade 3: 1.1% APBI v 0% WBI, P <.0001) were significantly higher in the APBI arm. There were no significant differences in late skin and lung toxicities.CONCLUSIONExternal beam radiation therapy-APBI with a twice-daily IRMA schedule was associated with increased rates of late moderate soft tissue and bone toxicities, with a slight decrease in patient-reported cosmetic outcomes at 5 years when compared with WBI, although overall toxicity was in an acceptable range.
AB - PURPOSEThe results in terms of side effects vary among the published accelerated partial-breast irradiation (APBI) studies. Here, we report the 5-year results for cosmetic outcomes and toxicity of the IRMA trial.METHODSWe ran this randomized phase III trial in 35 centers. Women with stage I-IIA breast cancer treated with breast-conserving surgery, age 49 years, were randomly assigned 1:1 to receive either whole-breast irradiation (WBI) or external beam radiation therapy APBI (38.5 Gy/10 fraction twice daily). Patients and investigators were not masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence. We hereby present the analysis of the secondary outcomes, cosmesis, and normal tissue toxicity. All side effects were graded with the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer Radiation Morbidity Scoring Schema. Analysis was performed with both intention-to-treat and as-treated approaches.RESULTSBetween March 2007 and March 2019, 3,309 patients were randomly assigned to 1,657 WBI and 1,652 APBI; 3,225 patients comprised the intention-to-treat population (1,623 WBI and 1,602 APBI). At a median follow-up of 5.6 (interquartile range, 4.0-8.4) years, adverse cosmesis in the APBI patients was higher than that in the WBI patients at 3 years (12.7% v 9.2%; P =.009) and at 5 years (14% v 9.8%; P =.012). Late soft tissue toxicity (grade 3: 2.8% APBI v 1% WBI, P <.0001) and late bone toxicity (grade 3: 1.1% APBI v 0% WBI, P <.0001) were significantly higher in the APBI arm. There were no significant differences in late skin and lung toxicities.CONCLUSIONExternal beam radiation therapy-APBI with a twice-daily IRMA schedule was associated with increased rates of late moderate soft tissue and bone toxicities, with a slight decrease in patient-reported cosmetic outcomes at 5 years when compared with WBI, although overall toxicity was in an acceptable range.
KW - PATIENT-REPORTED OUTCOMES
KW - CONSERVING THERAPY
KW - IN-SITU
KW - LONGITUDINAL ANALYSIS
KW - RADIATION-THERAPY
KW - CANCER
KW - RADIOTHERAPY
KW - SURGERY
KW - MASTECTOMY
KW - SURVIVAL
U2 - 10.1200/JCO.22.01485
DO - 10.1200/JCO.22.01485
M3 - Article
C2 - 36623246
SN - 0732-183X
VL - 41
SP - 2201
EP - 2210
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -